https://ijmri.de/index.php/jmsi
volume 4, issue 4, 2025
422
TREATMENT OF DYSBIOSIS DURING ANTIBIOTIC THERAPY FOR ACUTE
INTESTINAL INFECTIONS
Pulatov Muzaffar Ergashevich
Assistants of the Department of Infectious Diseases
Andighan State Medical Institute
Abstract:
Acute intestinal infections (AIIs) remain one of the most frequent causes of morbidity
across various age groups, particularly among children and immunocompromised patients.
Bacterial or mixed etiology infections often require antibiotic therapy, which can significantly
disrupt the gut microbiota. This dysbiosis may manifest clinically and lead to prolonged
gastrointestinal symptoms, malabsorption, and increased susceptibility to secondary infections.
This article reviews current knowledge regarding the pathophysiology of dysbiosis induced by
antibiotic treatment of AIIs and presents evidence-based strategies for restoring a balanced gut
microbiota. Key approaches include using probiotics, prebiotics, and synbiotics, alongside
antibiotic stewardship and careful monitoring of gastrointestinal function.
Keywords
: acute intestinal infections, antibiotics, dysbiosis, probiotics, gut microbiota,
antibiotic stewardship
ЛЕЧЕНИЕ ДИСБАКТЕРИОЗА ВО ВРЕМЯ АНТИБИОТИКОТЕРАПИИ ОСТРЫХ
КИШЕЧНЫХ ИНФЕКЦИЙ
Пулатов Музаффар Эргашевич
Ассистент кафедры инфекционных болезней
Андиганский государственный медицинский институт
Аннотация:
Острые кишечные инфекции (ОКИ) остаются одной из наиболее частых
причин заболеваемости в различных возрастных группах, особенно среди детей и
пациентов с ослабленным иммунитетом. Бактериальные или смешанные инфекции часто
требуют антибактериальной терапии, которая может значительно нарушить микробиоту
кишечника. Этот дисбактериоз может проявляться клинически и приводить к длительным
желудочно-кишечным симптомам, мальабсорбции и повышенной восприимчивости к
вторичным инфекциям. В этой статье рассматриваются современные знания о
патофизиологии дисбактериоза, вызванного антибиотикотерапией ОКИ, и представлены
научно обоснованные стратегии восстановления сбалансированной микробиоты
кишечника. Ключевые подходы включают использование пробиотиков, пребиотиков и
синбиотиков, а также рациональное использование антибиотиков и тщательный
мониторинг функции желудочно-кишечного тракта.
Ключевые слова:
острые кишечные инфекции, антибиотики, дисбактериоз, пробиотики,
микробиота кишечника, рациональное использование антибиотиков
INTRODUCTION
Acute intestinal infections (AIIs) are among the most common causes of acute gastroenteritis
worldwide, leading to significant morbidity and, in certain regions, elevated mortality, especially
https://ijmri.de/index.php/jmsi
volume 4, issue 4, 2025
423
in pediatric populations 111. Their etiological agents include bacteria (e.g.,
Salmonella spp.
,
Shigella spp.
, pathogenic
Escherichia coli
), viruses (rotavirus, norovirus), and protozoa [1].
Depending on the severity and cause, bacterial AIIs frequently necessitate antibiotic therapy.
While antibiotics can be lifesaving, they often disrupt the gut microbiome’s natural balance,
resulting in dysbiosis and associated complications 222.
The present article provides an overview of how antibiotic therapy contributes to dysbiosis
during AIIs, the clinical implications of this dysbiosis, and current evidence-based interventions
that aim to restore a healthy gut microbiota [2].
Etiology and pathogenesis of aii-related dysbiosis
Mechanisms of Antibiotic-Induced Dysbiosis - Antibiotics work by targeting bacterial pathogens,
but they also non-selectively impact commensal flora in the gut. Key mechanisms include:
Reduced Microbial Diversity: Broad-spectrum antibiotics can eradicate beneficial bacteria (e.g.,
Bifidobacterium
spp.,
Lactobacillus
spp.), diminishing overall richness and diversity of the
microbiome 333. Overgrowth of Resistant Strains: With commensals depleted, antibiotic-
resistant organisms (e.g.,
Clostridioides difficile
) can proliferate, leading to secondary infections
and inflammation. Metabolic Shifts: Loss of beneficial bacteria impairs short-chain fatty acid
(SCFA) production, influencing gut pH and epithelial integrity [3].
Clinical Manifestations - Prolonged Diarrhea: Antibiotic-associated diarrhea can be exacerbated
in an environment of ongoing intestinal infection. Malabsorption: Dysbiosis reduces the capacity
of the gut to digest and absorb nutrients. Recurrence or Persistence of Infection: An imbalanced
microbiota may fail to outcompete remaining pathogens [4]. Risk of Secondary Infections: The
prevalence of opportunistic pathogens (e.g.,
C. difficile
) increases under dysbiotic conditions.
DIAGNOSTIC CONSIDERATIONS
Microbiological Testing - Stool Culture: Useful for identifying primary pathogenic bacteria, as
well as any emerging resistant flora. Molecular Methods (PCR): Can detect low levels of
pathogenic bacteria or viruses, and sometimes quantify pathogenic or beneficial strains.
Microbiota Profiling - 16S rRNA Gene Sequencing: Provides insights into microbial community
composition. Although more common in research settings, next-generation sequencing
techniques are increasingly being used clinically to assess the extent of dysbiosis. Metabolomic
Analysis: Evaluates functional changes (e.g., SCFA production). Still largely in the research
phase but offers a deeper understanding of metabolic alterations [5].
Clinical markers - Inflammatory Markers: Elevated C-reactive protein (CRP) or fecal
calprotectin can indicate intestinal inflammation [6]. Symptom Assessment: Frequency of
diarrhea, abdominal pain, bloating, and presence of systemic symptoms help evaluate the
severity of dysbiosis.
TREATMENT STRATEGIES
Rational Antibiotic Therapy - Narrow-Spectrum Agents: Whenever possible, select agents that
specifically target the identified pathogen. Reducing the use of broad-spectrum antibiotics helps
preserve beneficial gut flora. Antibiotic Stewardship: Includes de-escalating therapy based on
pathogen sensitivities, limiting treatment duration, and avoiding inappropriate antibiotic use.
Probiotic Supplementation - Single-Strain Probiotics:
Lactobacillus rhamnosus GG
,
Saccharomyces boulardii
, and
Bifidobacterium
species are commonly used. Studies show they
can reduce the incidence and severity of antibiotic-associated diarrhea 444. Multi-Strain
Formulations: Combining different species may broaden the coverage and enhance resilience
against multiple pathogens [7]. Timing and Dosage: Probiotics are most effective when initiated
early in therapy and continued for at least 1–2 weeks post-antibiotic course. Dosages typically
range from 10^7 to 10^10 CFU/day, though optimal levels depend on specific strains.
https://ijmri.de/index.php/jmsi
volume 4, issue 4, 2025
424
Prebiotics and Synbiotics - Prebiotics: Non-digestible food ingredients (e.g.,
fructooligosaccharides, inulin) that selectively feed beneficial gut bacteria. Synbiotics:
Formulations that combine probiotics and prebiotics, aiming to improve probiotic survival and
colonization [8]. Dietary Fiber: Encouraging whole-grain foods, fruits, and vegetables can
enhance gut flora recovery.
Adjunctive Therapies - Enterosorbents (e.g., activated charcoal, smectite) can help bind bacterial
toxins, though their role in dysbiosis remains under investigation. Zinc Supplementation:
Particularly beneficial in pediatric populations, as zinc supports epithelial integrity and immune
function. Rehydration Therapy: Oral rehydration solutions are key to preventing dehydration in
patients with ongoing diarrheal symptoms.
Prevention and Long-Term Management
Vaccination - Preventing primary infections (e.g., rotavirus vaccine, COVID-19 vaccine,
influenza vaccine) can reduce the need for antibiotics and, hence, lower the risk of dysbiosis.
Infection control - Hand Hygiene and Sanitation: Reduces the transmission of pathogenic
bacteria and viruses. Isolation Precautions: In hospital settings, adherence to infection control
protocols can prevent healthcare-associated infections that complicate the patient’s
gastrointestinal condition.
Ongoing Microbiome Monitoring - In cases of severe or recurrent dysbiosis, periodic stool
analyses or other emerging diagnostics may guide personalized interventions, including targeted
probiotic use or dietary modifications.
DISCUSSION
Antibiotic-induced dysbiosis can prolong or worsen the clinical course of acute intestinal
infections, resulting in additional morbidity and extended convalescence. The gut microbiota
plays a critical protective role, acting as a barrier to pathogen colonization and contributing to
immune function. When antibiotics are necessary for life-threatening infections, the judicious
selection of agents and the concurrent or subsequent use of microbiome-supportive measures can
mitigate the negative impact on the gut ecosystem.
Challenges persist in identifying optimal probiotic strains, dosages, and durations for different
patient populations. Moreover, while current evidence supports the efficacy of many
commercially available products, further large-scale, randomized clinical trials are needed to
standardize best practices, especially in pediatric and immunocompromised individuals.
CONCLUSION
The management of dysbiosis during antibiotic therapy for acute intestinal infections necessitates
a multifaceted approach. Central to this is the rational use of antibiotics guided by precise
microbiological diagnoses, combined with probiotic supplementation, prebiotics, and synbiotics
to help restore intestinal homeostasis. Emphasizing antibiotic stewardship, promoting preventive
measures (e.g., vaccination), and advancing diagnostic techniques will contribute to improved
patient outcomes and a reduced burden of antibiotic-associated dysbiosis.
REFERENCES
1.
World Health Organization. Diarrheal disease.
(Accessed Feb 2025).
2.
Francino MP. Antibiotics and the human gut microbiome: Dysbioses and accumulation of
resistances.
Front Microbiol.
2016;7:1437.
3.
Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the
human distal gut microbiota to repeated antibiotic perturbation.
Proc Natl Acad Sci U S A.
2011;108 Suppl 1:4554–4561.
https://ijmri.de/index.php/jmsi
volume 4, issue 4, 2025
425
4.
Szajewska H, Canani RB, Guarino A, et al. Probiotics for the prevention of antibiotic-
associated diarrhea in children.
J Pediatr Gastroenterol Nutr.
2016;62(3):495–506.
5.
Akhatovna, M. K. (2023). BENEFITS OF COMPLETE TREATMENT OF
INFECTIOUS DIARRHEA IN YOUNG CHILDREN. Ethiopian International Journal of
Multidisciplinary Research, 10(10), 115-117.
6.
Mulladjanova, K. A., & Khodjimatov, G. M. (2021). Algorithm of Diagnosis,
Pathogenetic Treatment and Prevention of Acute Diarrhea in Early Children. Annals of the
Romanian Society for Cell Biology, 25(1), 6355-6363.
7.
Mutalibovich, Q. A. (2024). ENTEROVIRAL INFECTIONS: MODERN FEATURES.
Ethiopian International Journal of Multidisciplinary Research, 11(02), 199-200.
8.
Saidakbarovich, M. A. (2023). INTRAUTERINE INFECTIONS: A MODERN VIEW
AT THE PROBLEM. International Journal of Medical Sciences And Clinical Research, 3(10),
79-82.
